Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
Source: Globenewswire
Phase 1 Clinical Trial Initiation: Radiopharm Theranostics has commenced the Phase 1 'HEAT' clinical trial for RAD202, a novel radiotherapeutic targeting HER2-positive advanced solid tumors, to assess safety, tolerability, and preliminary efficacy in patients.
Significance of HER2 Targeting: The trial aims to provide new therapeutic options for patients with metastatic HER2-positive cancers who have limited treatment alternatives, building on previous proof-of-concept data that demonstrated RAD202's safety and biodistribution in humans.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
